28.43 USD
-0.48
1.66%
At close Dec 5, 4:00 PM EST
After hours
28.43
+0.00
0.00%
1 day
-1.66%
5 days
-0.66%
1 month
12.15%
3 months
0.89%
6 months
7.69%
Year to date
-14.29%
1 year
-8.02%
5 years
-45.13%
10 years
-81.91%
 

About: Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Employees: 9,140

0
Funds holding %
of 6,790 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

390% more call options, than puts

Call options by funds: $54.2M | Put options by funds: $11.1M

8% more repeat investments, than reductions

Existing positions increased: 131 | Existing positions reduced: 121

2% more capital invested

Capital invested by funds: $3.34B [Q2] → $3.42B (+$79.3M) [Q3]

0.18% more ownership

Funds ownership: 95.49% [Q2] → 95.67% (+0.18%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 9 [Q2] → 9 (+0) [Q3]

4% less funds holding

Funds holding: 355 [Q2] → 342 (-13) [Q3]

23% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 56

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$30
6%
upside
Avg. target
$36
27%
upside
High target
$42
48%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Canaccord Genuity
Susan Anderson
61% 1-year accuracy
11 / 18 met price target
48%upside
$42
Buy
Maintained
30 Sept 2024
Jefferies
Keith Devas
100% 1-year accuracy
1 / 1 met price target
6%upside
$30
Hold
Downgraded
23 Sept 2024

Financial journalist opinion

Based on 7 articles about PRGO published over the past 30 days

Positive
Seeking Alpha
2 weeks ago
Perrigo Company: Great Combination Of Future Growth With A Low Valuation
Perrigo's long-term growth is driven by strategic initiatives like Project Energize, aiming for $140-$170 million in annualized savings by 2026. The company's reinvestments in leadership and IT, adding 200 years of consumer experience, are crucial for sustainable growth. Perrigo's supply chain reinvention program has already achieved $72 million in gross savings, enhancing cash flow and operational efficiency.
Perrigo Company: Great Combination Of Future Growth With A Low Valuation
Negative
Zacks Investment Research
3 weeks ago
Perrigo (PRGO) International Revenue Performance Explored
Review Perrigo's (PRGO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Perrigo (PRGO) International Revenue Performance Explored
Negative
Zacks Investment Research
4 weeks ago
Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated
PRGO reports weaker-than-expected third-quarter 2024 results. Though management updates top-line guidance for 2024, it reaffirms the bottom-line outlook.
Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated
Neutral
Seeking Alpha
4 weeks ago
Perrigo Company plc (PRGO) Q3 2024 Earnings Call Transcript
Perrigo Company plc (NYSE:PRGO ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Bradley Joseph - Vice President of Global Investor Relations Patrick Lockwood-Taylor - President & Chief Executive Officer Eduardo Bezerra - Chief Financial Officer Conference Call Participants Susan Anderson - Canaccord Keith Devas - Jefferies Korinne Wolfmeyer - Piper Sandler Daniel Biolsi - Hedgeye Operator Good morning, ladies and gentlemen and welcome to the Perrigo Third Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode.
Perrigo Company plc (PRGO) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
4 weeks ago
Perrigo (PRGO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Perrigo (PRGO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Negative
Zacks Investment Research
4 weeks ago
Perrigo (PRGO) Q3 Earnings and Revenues Lag Estimates
Perrigo (PRGO) came out with quarterly earnings of $0.81 per share, missing the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.64 per share a year ago.
Perrigo (PRGO) Q3 Earnings and Revenues Lag Estimates
Neutral
PRNewsWire
4 weeks ago
Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations
Company Delivered Solid Third Quarter Financial Results, Including Meaningful Operating Income Growth and Margin Expansion Infant Formula Business Recovery Making Significant Progress, Including Perrigo Produced and Store Brand Infant Formula Market Share Gains1; Third Quarter 2024 Infant formula Net Sales Growth of +3% Compared to the Prior Year Quarter, +58% Sequentially Reaffirms Fiscal 2024 Adjusted EPS Outlook DUBLIN , Nov. 6, 2024 /PRNewswire/ -- Third Quarter 2024 Highlights: Net sales of $1.1 billion declined 3.2% versus the prior year quarter. Organic2 net sales decreased 2.4%, due primarily to -2.8 percentage points from previously disclosed lost distribution of lower margin products in U.S. Store Brand.
Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations
Negative
Zacks Investment Research
1 month ago
Perrigo to Report Q3 Earnings: Here's What to Expect
PRGO's Q3 top line is expected to have been affected by lower net product sales in the United States and unfavorable currency movements in the quarter.
Perrigo to Report Q3 Earnings: Here's What to Expect
Neutral
PRNewsWire
1 month ago
Perrigo Announces Quarterly Dividend
DUBLIN , Nov. 1, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on December 17, 2024, to shareholders of record on November 29, 2024. About Perrigo   Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.
Perrigo Announces Quarterly Dividend
Neutral
Zacks Investment Research
1 month ago
Perrigo (PRGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo (PRGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Charts implemented using Lightweight Charts™